Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Teucrium Wheat Fund (WEAT) Price & Performance

Regeneron Pharmaceuticals IncTrade
Teucrium Wheat FundTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Teucrium Wheat Fund trades at $26.3. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals.

REGNWEAT
Market Cap
$83.43B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$852.03$28.00
52-Week Low
$555.51$19.88
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Teucrium Wheat Fund

WEAT, a US-listed wheat ETF, trades at $26.96, up 1.77% today, with a bullish technical signal from moving averages and ADX indicating strong trend momentum. Recent performance shows a 9.9% gain over the past month, driven by inflation concerns and commodity strength. Key support and resistance cluster around $27, suggesting a pivotal price zone.

Outlook remains positive due to inflation hedging demand, but risks include commodity price volatility and Federal Reserve policy shifts. The ETF lacks traditional fundamental metrics like P/E or revenue, relying on wheat futures performance. Investors should weigh macroeconomic trends against potential pullbacks in agricultural markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Teucrium Wheat Fund

WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.

Read more on WEAT